Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel (Plavix®) Following Percutaneous Coronary Intervention: A Prospective Multicenter Cohort Study

NCT07876336 is registered in ClinicalTrials.gov with October 6 University as lead sponsor.

NCT NCT07876336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07876336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel (Plavix®) Following Percutaneous Coronary Intervention: A Prospective Multicenter Cohort Study
Lead sponsor
October 6 University
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 1, 2026
Completion date
June 30, 2027
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome (acs) undergoing percutaneous coronary intervention (pci)